The prognostic value of midregional proatrial natriuretic peptide in patients with hemorrhagic stroke.

Fischer, Marlene; Katan, Mira; Morgenthaler, Nils G.; Seiler, Marleen; Müller, Beat; Lackner, Peter; Errath, Mario; Helbok, Raimund; Pfausler, Bettina; Beer, Ronny; Schmutzhard, Erich; Broessner, Gregor

doi:10.1159/000357215

Record: found
Abstract: found
Article: found

The prognostic value of midregional proatrial natriuretic peptide in patients with hemorrhagic stroke.

Author(s): Marlene Fischer ¹ , Mira Katan , Nils G Morgenthaler , Marleen Seiler , Beat Müller , Peter Lackner , Mario Errath , Raimund Helbok , Bettina Pfausler , Ronny Beer , Erich Schmutzhard , Gregor Broessner

Publication date (Electronic): 2014

Journal: Cerebrovascular diseases (Basel, Switzerland)

Publisher: S. Karger AG

Read this article at

ScienceOpenPublisher PubMed

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Atrial natriuretic peptide (ANP) is a well-known prognostic marker of outcome and mortality in patients with cardiovascular disease. Midregional proatrial natriuretic peptide (MR-proANP) is a stable fragment of the ANP precursor hormone. As a prognostic marker after ischemic stroke, it reliably predicts poststroke mortality and functional outcome. This study aimed to analyze the prognostic value of MR-proANP in patients with hemorrhagic stroke, i.e. subarachnoid (SAH) and intracerebral hemorrhage (ICH).